Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) rose 4.4% during mid-day trading on Friday . The stock traded as high as $3.37 and last traded at $3.32, with a volume of 272,651 shares changing hands. The stock had previously closed at $3.18.

RGLS has been the subject of several recent research reports. Wedbush reaffirmed a “buy” rating on shares of Regulus Therapeutics in a research report on Saturday, March 19th. BMO Capital Markets assumed coverage on shares of Regulus Therapeutics in a research report on Monday, April 11th. They issued an “outperform” rating and a $16.00 price objective for the company. Chardan Capital assumed coverage on Regulus Therapeutics in a research note on Wednesday, April 13th. They set a “buy” rating and a $15.00 target price for the company. FBR & Co reiterated a “buy” rating and set a $30.00 target price on shares of Regulus Therapeutics in a research note on Sunday, April 17th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Regulus Therapeutics in a research note on Tuesday, May 3rd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $10.42.

The stock’s market cap is $175.23 million. The stock has a 50-day moving average price of $4.78 and a 200-day moving average price of $6.19.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.07. On average, equities research analysts anticipate that Regulus Therapeutics Inc. will post ($1.54) EPS for the current year.

An institutional investor recently bought a new position in Regulus Therapeutics stock. Oxford Asset Management acquired a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 260,798 shares of the biopharmaceutical company’s stock, valued at approximately $2,335,000. Oxford Asset Management owned about 0.50% of Regulus Therapeutics as of its most recent filing with the SEC.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.